Biomarker Tests and Gaps in Legal Protection
Penn LDI14 Oct · 03:18← All topics · now
Development ↘
Development ↘
Development ↘
Development ↘
Development ↘
Development ↘
Right now
A blood biomarker tracks brain amyloid similarly across racial groups, supporting equitable diagnosis.
14 reports · the last 24 hours
Summary · from headlines5 points
- JAMA reported %p-Tau217 by race and ethnicity in preclinical AD.
- Early Alzheimer’s biomarker test results boost diagnostic certainty and guide clinical care.
- A routine blood test may suggest future dementia risk.
- An Alzheimer’s blood biomarker tracks brain amyloid similarly across racial groups, a study finds.
- Biomarker tests and gaps in legal protection were examined.
Latest developments6 to read first
Large global study examines Alzheimer’s blood biomarker across racial and ethnic groups
Keck School of Medicine of USC14 Oct · 02:38Alzheimer's blood biomarker tracks brain amyloid similarly across racial groups, study finds
Medical Xpress14 Oct · 02:38Routine blood test may suggest future dementia risk
Medical Xpress13 Oct · 18:34New Alzheimer’s treatments, testing offer hope for slowing cognitive decline
Boston 25 News13 Oct · 18:34Promising advancements in Alzheimer's disease management
Antigo Times13 Oct · 18:34Timeline 14 reports
14 Oct 20263 reportsToday
03:001 report
02:002 reports
13 Oct 202611 reports
18:004 reports
17:00nothing heard
16:001 report
15:00nothing heard
14:00nothing heard
13:00nothing heard
12:00nothing heard
11:002 reports
10:00nothing heard
09:00nothing heard
08:00nothing heard
07:002 reports
06:00nothing heard
05:002 reports
← All topics · nowOne topic